Human Insulin Market – Overview

Human insulin is also known as synthetic insulin which is prepared in laboratory and has same characteristics like natural insulin. Human insulin was developed through the 1960s and 1970s and approved for pharmaceutical use in 1982. Before the invention of human insulin animal insulin, usually a purified form of porcine was used.

According to a recent study report published by the Market Research Future, the global market for Human Insulin Market is expected to reach up to $40 billion by the end of the forecasted period and is expected to grow at a CAGR of ~10-12% during the forecast period.

Today, approximately 100 million people around the world need insulin, including all people living with type 1 diabetes and between 10-25 percent of people with type 2 diabetes. Although recombinant human insulin has been used in the treatment of diabetes for over 90 years, globally more than half of those who need insulin today still cannot afford it. Without insulin, people living with type 1 diabetes will die. Many more will suffer from diabetes-related complications, like blindness, amputation and kidney failure, and, ultimately, premature death. There are many complex issues that affect access to this life-saving medicine, creating inequity and inefficiency in the global insulin market. These issues include the global insulin market domination by three multinational manufacturers, import duties affecting the price insulin entering different countries, and mark-ups, taxes and other charges in the public and private sector supply chains that affect the final patient price.

Human Insulin Market   –   Regional Analysis

Geographically, North America has the largest share in global human insulin market; large share of this market is attributed to the growing prevalence of diabetes and obesity. The North American market for human insulin is expected to grow at a significant rate of CAGR and is expected to reach at multimillions of USD by the end of the forecasted period. Europe is the second-largest market for human insulin, which is expected to grow at a Considerable rate of CAGR. Asia-Pacific has emerged as the fastest growing region.

Human Insulin Market   – Segments

Global Human Insulin market has been segmented on the basis of types which majorly includes modern human insulin, and traditional human insulin. The modern human insulin is further divided into; long acting human insulin, rapid acting human insulin, and premixed human insulin. Whereas, the traditional human insulin is again categorized into; short acting human insulin, and intermediate acting human insulin.

Based on the type, modern human insulin has the largest market share in the human insulin market

Human Insulin Market Players

• Biocon Ltd. (India),
• Tonghua Dongbao Pharmaceuticals Co., Ltd. (China),
• Adocia (France.),
• Merck Co. (U.S.),
• Julphar (UAE),
• Bristol-Myers Squibb Company (U.S.).

among others are some key companies in the global Human Insulin that are listed by MRFR for market research.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]